Treatment-damaged hepatocellular carcinoma promotes activities of hepatic stellate cells and fibrosis through GDF15
- 7 July 2018
- journal article
- research article
- Published by Elsevier BV in Experimental Cell Research
- Vol. 370 (2), 468-477
- https://doi.org/10.1016/j.yexcr.2018.07.011
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China (81272723, 81472217)
This publication has 25 references indexed in Scilit:
- Morbidity and mortality following transarterial liver chemoembolization in patients with hepatocellular carcinoma and synthetic hepatic dysfunctionLiver Transplantation, 2012
- The influence on liver function after transcatheter arterial chemoembolization combined with percutaneous radiofrequency ablation in patients with hepatocellular carcinomaJournal of the Formosan Medical Association, 2012
- Metformin-Mediated Bambi Expression in Hepatic Stellate Cells Induces Prosurvival Wnt/β-Catenin SignalingCancer Prevention Research, 2012
- Transarterial Chemoembolization Complicated by Deteriorating Hepatic FunctionSeminars in Interventional Radiology, 2011
- p53 controls prostate-derived factor/macrophage inhibitory cytokine/NSAID-activated gene expression in response to cell density, DNA damage and hypoxia through diverse mechanismsCancer Letters, 2009
- Macrophage Inhibitory Cytokine-1: Possible Bridge Molecule of Inflammation and Prostate CancerCancer Research, 2008
- Management of hepatocellular carcinomaJournal of Hepatology, 2005
- The ERK Cascade: A Prototype of MAPK SignalingMolecular Biotechnology, 2005
- Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trialThe Lancet, 2002
- Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinomaJournal of Hepatology, 2002